Cited 13 times in
PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 심효섭 | - |
dc.contributor.author | 차윤진 | - |
dc.date.accessioned | 2018-07-20T08:38:12Z | - |
dc.date.available | 2018-07-20T08:38:12Z | - |
dc.date.issued | 2017 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161337 | - |
dc.description.abstract | Background: Inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal neoplasms that are composed of myofibroblastic cells accompanied by inflammatory infiltrate. We investigated the immune profiles of IMTs, including PD-L1 expression and proportion of CD8+ tumor-infiltrating lymphocytes (TILs), as well as its clinicopathological characteristics according to ALK gene rearrangementstatus. Methods: Twenty-eight IMTs from 25 patients were retrieved from our pathology files (2005-2015), and their clinicopathological parameters and outcomes were analyzed. Immunohistochemistry (IHC) was performed using whole-tissue sections to detect PD-L1 and CD8 expression, and fluorescent in situ hybridization (FISH) analysis and IHC were performed using tissue microarrays to identify rearrangements in the ALK, ROS1, and RET genes. Results: ALK rearrangement was observed in 11 cases (44.0%), and all cases exhibited diffuse cytoplasmic ALK expression during IHC. ROS1 or RET rearrangement was not detected using IHC or FISH. IMTs harboring ALK rearrangement (ALK-positive) were located in the lungs (n = 7), genitourinary tract (n = 2), and mesentery (n = 1). The mean patient age was 33.2 years for ALK-positive IMTs and 53.1 years for ALK-negative IMTs. All patients with ALK-positive IMTs survived without recurrence or metastasis. IMTs with metastasis and/or recurrence were ALK-negative and exhibited elevated PD-L1 expression (positive tumor cells: 70.0% vs. 21.3%, P = 0.023; H-score: 107.5 vs. 26.3, P = 0.005). In addition, ALK-negative IMTs had a more CD8+ TILs, compared to ALK-positive IMTs (23.3% vs. 8.9%, P = 0.027). Conclusion: ALK-positive IMTs are characterized by younger age, well-defined margins, frequent involvement of the lung, and fewer CD8+ TILs. Greater PD-L1 expression was observed in IMTs with tumor necrosis and metastasis/recurrence, which were also negative for ALK rearrangement. These results suggest that immune checkpoint inhibitors may be a novel option for treating patients with advanced IMT. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Impact Journals | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Pathology | - |
dc.contributor.googleauthor | Yoon Jin Cha | - |
dc.contributor.googleauthor | Hyo Sup Shim | - |
dc.identifier.doi | 10.18632/oncotarget.20948 | - |
dc.contributor.localId | A02219 | - |
dc.contributor.localId | A04001 | - |
dc.relation.journalcode | J02421 | - |
dc.identifier.eissn | 1949-2553 | - |
dc.identifier.pmid | 29163763 | - |
dc.subject.keyword | PD-L1 | - |
dc.subject.keyword | Pathology Section | - |
dc.subject.keyword | anaplastic lymphoma kinase | - |
dc.subject.keyword | inflammatory | - |
dc.subject.keyword | lymphocyte | - |
dc.subject.keyword | myofibroblastic tumor | - |
dc.contributor.alternativeName | Shim, Hyo Sup | - |
dc.contributor.alternativeName | Cha, Yoon Jin | - |
dc.contributor.affiliatedAuthor | Shim, Hyo Sup | - |
dc.contributor.affiliatedAuthor | Cha, Yoon Jin | - |
dc.citation.volume | 8 | - |
dc.citation.number | 52 | - |
dc.citation.startPage | 89465 | - |
dc.citation.endPage | 89474 | - |
dc.identifier.bibliographicCitation | ONCOTARGET , Vol.8(52) : 89465-89474, 2017 | - |
dc.identifier.rimsid | 61256 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.